Navigation Links
Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
Date:5/14/2009

CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Orlando, Florida May 29-June 2, 2009. The abstracts are available on the ASCO website today at www.asco.org.

    REOLYSIN poster presentations

    -   Dr. Monica Mita and colleagues are scheduled to deliver a poster
        presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type
        Reovirus in the Treatment of Patients with Bone and Soft Tissue
        Sarcomas Metastatic to the Lung."

    -   Dr. Johann de Bono and colleagues are scheduled to deliver a poster
        presentation entitled "A Phase I Study of the Combination of
        Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts)
        with Advanced Cancer."

    -   Dr. Sanjay Goel and colleagues are scheduled to deliver a poster
        entitled "Dose Escalation and Pharmacodynamic Study of Intravenous
        Administration of REOLYSIN, a Live Replication Competent RNA Virus in
        Patients with Advanced Solid Tumors."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials to be presented at this meeting with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... ... 2017 , ... Dr. Joshua Mondlick has introduced the LANAP® protocol to treat ... Perio, in the Phoenix area. Dr. Mondlick is at the forefront of the ... treatment to re-grow bone and with significantly less pain than traditional surgery options. , ...
(Date:7/14/2017)... USA/ Martinsried, Germany (PRWEB) , ... July 14, ... ... newly developed standardized solution for sample preparation of proteins to clean peptides for ... Diagenode Bioruptor® sonication system. , The PreOmics iST Kit is based on ...
(Date:7/13/2017)... ... July 13, 2017 , ... Heritage Biologics is ... is the independent leader in promoting healthcare quality through accreditation, certification and measurement. ... care, improved processes and better patient outcomes. , ÔÇťAchieving URAC accreditation is ...
(Date:7/13/2017)... ... 13, 2017 , ... FireflySci Inc. started manufacturing calibration standards ... years and now they are home to a tremendous line of certified calibration ... resolution testing. , One mega advantage that FireflySci brings to the ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):